Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25

European Journal of Biochemistry

Volumn 267, Issue 19, 2000, Pages 5983-5994

  Leost, Maryse ^a   Schultz, Christiane ^b   Link, Andreas ^b   Wu, Yong Zhong ^c   Biernat, Jacek ^c   Mandelkow, Eva Maria ^c   Bibb, James A ^d   Snyder, Gretchen L ^d   Greengard, Paul ^d   Zaharevitz, Daniel W ^e   Gussio, Rick ^e   Senderowicz, Adrian M ^e   Sausville, Edward A ^e   Kunick, Conrad ^b   Meijer, Laurent ^a  

^a STATION BIOLOGIQUE   (France)

^b UNIVERSITY OF HAMBURG   (Germany)

^c MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

^d ROCKEFELLER UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Cyclin dependent kinase 5; Glycogen synthase kinase 3; Paullones, kinase inhibitors

Indexed keywords

ALSTERPAULLONE; BENZAZEPINE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALIA;

EID: 0033798031     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01673.x     Document Type: Article

References (103)

1. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
2. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification
3. Cyclin-dependent kinases: Engines, clocks and microprocessors
4. Cell multiplication - Peering in and peering out: Regulation of and by the cell cycle
5. Mechanisms of cyclin-dependent kinase regulation: Structures of cdks, their cyclin activators, and Cip and INK4 inhibitors
6. Cell cycle: Driving the centrosome cycle
7. β-Catenin: A key regulator of Wnt signaling
8. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3
9. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
10. Glycogen synthase kinase 3 and dorso-ventral pattering in Xenopus embryos
11. GSK-3β/Shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo
12. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction
13. The role of glycogen synthase kinase 3β in insulin-stimulated glucose metabolism
14. Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium
15. HIV-1 Tat-mediated activation of glycogen synthase kinase-3β contributes to tat-mediated neurotoxicity
16. Uber eine eigenartige erkrankung der himrinde
17. Alzheimer's disease
18. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease
19. Purification of tau, a microtubule associated protein that induces assembly of microtubules from purified tubulin
20. Microtubule-associated protein tau: Biochemical modifications, degradation and Alzheimer's disease
21. Tau in Alzheimer's disease
22. Proteolysis by presenilins and the renaissance of tau
23. Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders
24. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease
25. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthas ekinase-3 in transfected mammalian cells
26. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3 beta transgenes
27. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau
28. Presenilins. Structural aspects and post-translational events
29. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
30. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau
31. A family of human cdc2-related protein kinases
32. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's
33. A cdc-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule
34. Cyclin-dependent kinase 5 (CDK5) and neuron-specific cdk5 activators
35. A brain-specific activator of cyclin-dependent kinase 5
36. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of Cdk5 in bovine brain
37. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5
38. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
39. Elevated neuronal cdc2-like kinase activity in the Alzheimer disease brain
40. Potentiation of GSK-3-catalysed Alzheimer-like phosphorylation of human tau by cdk5
41. Preferential labelling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3β and cyclin-dependent kinase 5, a componenet of TPK II
42. Sequential phosphorylation of tau-protein by GSK-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT-100 and requires a paired helical filament-like conformation
43. Protein kinase-A and glycogen synthase kinase-3 in combination hyperphosphorylate Tau to an Alzheimer's disease state
44. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease
45. Phosphorylation of tau protein by casein kinase 1 converts it to an abnormal Alzheimer-like state
46. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease
47. Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation
48. The development and therapeutic potential of protein kinase inhibitors
49. ATP-site directed kinase inhibitors for therapeutic intervention
50. Proceedings of the first international conference on inhibitors of protein kinases
51. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation
52. Cyclin-dependent kinase inhibition and cancer therapy
53. ATP-site directed inhibitors of cyclin-dependent kinases
54. Properties and potential applications of chemical inhibitors of cyclin-dependent kinases
55. Inhibition of cyclin-dependent kinases by purine derivatives
56. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
57. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors
58. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors
59. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
60. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase
61. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
62. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent
63. Fused azepinones with antitumor activity
64. The paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
65. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
66. A molecular mechanism for the effect of lithium on development
67. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells
68. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220 are potent inhibitors of glycogen synthase kinase-3 activity
69. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations
70. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
71. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3b-dependent phosphorylation of juvenile tau in cultured hippocampal neurons
72. Carcinogenic nitrogen compounds. Part XI. Indeno (3': 2'-2: 3) indoles, benzindeno (3': 2'-2: 3) indoles, and related compounds
73. Antitumor pyrido[3,2-d][1]benzazepines: Synthesis and in vitro activity of thiophene analogs
74. d-Fused [1]benzazepines with selective in vitro antitumor activity: Synthesis and structure-activity relationships
75. 2-Substituted paullones: CDK1/cyclin B - Inhibiting property and in vitro antiproliferative activity
76. Synthese [b]-kondensierter azepindione durch dealkoxycarbonylierung
77. Baculovirus-mediated expression and characterisation of rat glycogen synthase kinase-3β, the mammalian homologue of the Drosophila melanogaster zestewhite homeotic gene product
78. Intra-M Phase-promoting factor phosphorylation of cyclin B at the prophase/metaphase transition
79. Phosphorylation of serine 262 strongly reduces the binding of tau protein to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding
80. The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains
81. Bidirectional regulation of DARPP-32 phosphorylation by dopamine
82. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons
83. Phosphorylation of tau protein by recombinant GSK-3β: Pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain
84. The endogenous and cell-cycle dependent phosphorylation of tau protein in living cells: Implications for Alzheimer's disease
85. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
86. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised ligants
87. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
88. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
89. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway
90. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease
91. Ectopic cell cycle proteins predict sites of neuronal cell death in AD brain
92. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain
93. Abnormal expression of the cell cycle regulators p16 and CDK4 in Alzheimer's disease
94. Abortive oncogeny and cell-cycle-mediated events in Alzheimer disease
95. Involvement of cell cycle elements, cyclin-dependent kinases, pRb and E2F.DP, in B-amyloid-induced neuronal death
96. Mitotic signaling by β-amyloid causes neuronal death
97. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons
98. Cyclin-dependnet kinases participate in death of neurons evoked by DNA-damaging agents
99. Caspase-dependent Cdk activity is a requisite effector of apoptotic death events
100. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal